Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
- PMID: 32286543
- DOI: 10.1038/s41375-020-0833-x
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
References
-
- Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, et al. Lancet Haematol. 2019;6:e366–74. - DOI
-
- Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124:49–62. - DOI
-
- Hosmer D, Lemeshow S. Applied logistic regression. 2nd ed. New York, NY: John Wiley & Sons, Inc.; 2000. p. 156–64.
-
- Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, et al. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. Haematologica. 2018;103:1209–17. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources